Circulating tumor cells

Ready for prime time

Kert D. Sabbath, Lee Schwartzberg

Research output: Contribution to journalReview article

Abstract

Although the prognosis for patients with advanced disease has improved significantly over the past 2 decades, most still die of uncontrollable disease. Once a malignancy has developed systemic spread, treatment is usually palliative, lethal effects for the vast majority of malignant neoplasms are due to systemic metastases causing organ dysfunction and death of the host. Metastatic disease can be detected by physical examination, but imaging studies are generally used to document the presence of disease and assess the response to treatment. The ability to isolate and evaluate circulating tumor cells (CTCs) is a potentially valuable tool to understand metastatic cancer.

Original languageEnglish (US)
JournalCommunity Oncology
Volume5
Issue number9
DOIs
StatePublished - Jan 1 2008

Fingerprint

Circulating Neoplastic Cells
Neoplasms
Physical Examination
Neoplasm Metastasis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Circulating tumor cells : Ready for prime time. / Sabbath, Kert D.; Schwartzberg, Lee.

In: Community Oncology, Vol. 5, No. 9, 01.01.2008.

Research output: Contribution to journalReview article

@article{f2f08f7f838d43409b2bd02816400fc5,
title = "Circulating tumor cells: Ready for prime time",
abstract = "Although the prognosis for patients with advanced disease has improved significantly over the past 2 decades, most still die of uncontrollable disease. Once a malignancy has developed systemic spread, treatment is usually palliative, lethal effects for the vast majority of malignant neoplasms are due to systemic metastases causing organ dysfunction and death of the host. Metastatic disease can be detected by physical examination, but imaging studies are generally used to document the presence of disease and assess the response to treatment. The ability to isolate and evaluate circulating tumor cells (CTCs) is a potentially valuable tool to understand metastatic cancer.",
author = "Sabbath, {Kert D.} and Lee Schwartzberg",
year = "2008",
month = "1",
day = "1",
doi = "10.1016/S1548-5315(11)70504-6",
language = "English (US)",
volume = "5",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "9",

}

TY - JOUR

T1 - Circulating tumor cells

T2 - Ready for prime time

AU - Sabbath, Kert D.

AU - Schwartzberg, Lee

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Although the prognosis for patients with advanced disease has improved significantly over the past 2 decades, most still die of uncontrollable disease. Once a malignancy has developed systemic spread, treatment is usually palliative, lethal effects for the vast majority of malignant neoplasms are due to systemic metastases causing organ dysfunction and death of the host. Metastatic disease can be detected by physical examination, but imaging studies are generally used to document the presence of disease and assess the response to treatment. The ability to isolate and evaluate circulating tumor cells (CTCs) is a potentially valuable tool to understand metastatic cancer.

AB - Although the prognosis for patients with advanced disease has improved significantly over the past 2 decades, most still die of uncontrollable disease. Once a malignancy has developed systemic spread, treatment is usually palliative, lethal effects for the vast majority of malignant neoplasms are due to systemic metastases causing organ dysfunction and death of the host. Metastatic disease can be detected by physical examination, but imaging studies are generally used to document the presence of disease and assess the response to treatment. The ability to isolate and evaluate circulating tumor cells (CTCs) is a potentially valuable tool to understand metastatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=54749136543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54749136543&partnerID=8YFLogxK

U2 - 10.1016/S1548-5315(11)70504-6

DO - 10.1016/S1548-5315(11)70504-6

M3 - Review article

VL - 5

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 9

ER -